This is because cetuximab chemotherapy is challenged with chemoresistance, and may even trigger uncontrolled cell proliferation, cell growth, and even metastases in CRC patients with a mutation of either BRAF or KRAS genes [140,141]. The gene discussed is KRAS; the disease is colorectal carcinoma.